News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Mynet Finans Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article analyzes Instil Bio Inc. (NYSE: TIL) using AI models to suggest trading strategies based on price action. It identifies neutral readings in shorter horizons, potentially signaling an easing of a long-term weak bias, and highlights compelling upside potential with no remaining resistance …
Instil Bio (Nasdaq: TIL) reported a significantly trimmed net loss of $4.3 million in Q2 2026, down from $21.4 million in Q2 2025, driven by reduced operating expenses. The company also announced a strong cash position of $69.9 million, which is expected to fund …
Instil Bio, Inc. reported its 2026 quarterly results, showing a significantly narrower net loss and reduced comprehensive loss compared to the previous year. This improvement is attributed to the company winding down development of its lead candidate, AXN-2510, and substantially cutting R&D activity and …
This article reports on the filing of Form 8K by Instil Bio Inc. on August 13th, as tracked by Investing.com. The content itself is very brief, serving primarily as an announcement of the filing rather than providing detailed information about the filing's contents. It …
Instil Bio, Inc. (Nasdaq: TIL) reported its second quarter 2026 financial results, highlighting a cash position of approximately $69.9 million as of June 30, 2026, which is expected to fund operations beyond 2027. The biotechnology company is also actively evaluating potential acquisitions, in-licensing, and …
Instil Bio (TIL) significantly reduced operating expenses and narrowed its net loss in Q2 2026 due to the discontinuation of certain R&D programs and restructuring efforts. The company reported a net loss of $4.3 million for the quarter and $8.5 million for the first …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The fair value estimate for Sibanye Stillwater has been reset from ZAR65.41 to ZAR47.27 …
Sharemaestro market context Price below Trend Line 52 weeks +18.4%The article provides a brief overview of Instil Bio Inc (TIL) stock information, including its current price, market cap, and a note that more news is coming soon. It highlights key financial data points and directs users to follow the latest news, earnings, and …
Instil Bio, Inc. is projected to report a loss of 43 cents per share, according to an earnings preview. The article, sourced from Reuters, provides this financial expectation for the company.
This article provides an earnings forecast for Instil Bio Inc (TIL), detailing its current earnings forecast score, average price target, and analyst ratings. Based on three analysts, the stock has an average price target of $88.00 and a "Buy" recommendation. The article also addresses …
This article analyzes Instil Bio Inc. (NYSE: TIL), indicating a near-term neutral sentiment suggesting a pause in its mid and long-term weakness. It identifies compelling upside potential due to the absence of resistance levels above the current price. The report also outlines three AI-generated …
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Instil Bio, Inc. (NASDAQ: TIL) on behalf of investors who purchased the company's securities. This investigation follows a significant 45.81% drop in Instil's stock price on January 6, 2026, after its subsidiary, Axion Bio, …
This article provides an overview of Instil Bio Inc's (TIL) historical dividend payouts and stock split events. It indicates that Instil Bio has not distributed any dividends in the past five years. However, the company executed a 20-to-1 merger-related stock split on December 5, …
This article provides a valuation analysis for Instil Bio Inc (TIL), detailing its current stock price and a valuation score of 8.29 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio, noting its position relative to recent highs and lows. …
Search by ticker symbol or company name and select a result to open its chart.